INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.
Holding Company · BIOTCayman Islands · Tokyo
Disclosure Policy

Transparent, timely, and fair.

Our commitment to fair and equitable disclosure to investors.

Last Updatedv1.1

INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (the "Company") discloses information in accordance with the following policy to enable all stakeholders, including investors and shareholders, to properly assess our corporate value.

01

Fundamental Disclosure Principles

The Company is committed to timely, appropriate, and fair disclosure to investors, shareholders, and other stakeholders. We comply with applicable laws and NASDAQ disclosure rules and provide information in good faith to promote an accurate understanding of our corporate value.

02

Information to be Disclosed

We disclose financial information, business strategy, governance structure, risk factors, material business developments, and any other information that may affect investment decisions. In particular, we appropriately publish earnings releases, annual and periodic reports, internal control reports, current reports, and other timely disclosure information.

03

Methods of Disclosure

Regulatory filings are made through the SEC's EDGAR system. We also broadly and equitably provide information through the IR section of our corporate website, press releases, and investor briefings as appropriate.

04

Ensuring Fairness

We avoid providing information preferentially to particular investors or analysts and strive to ensure that all stakeholders can access the same information simultaneously. We strictly manage inside information and prevent selective disclosure.

05

Forward-Looking Information

Forward-looking statements we disclose are predictions based on information available at the time of disclosure and involve risks and uncertainties. Actual results may differ materially due to market conditions, competitive developments, regulatory changes, and other factors.

06

Disclosure Framework

We maintain a disclosure control structure headed by the Chairman and CEO as the responsible officer, with legal, finance, and IR teams collaborating to verify the appropriateness of disclosed information. We consult external experts as needed and continuously strive to improve disclosure quality.

07

Inquiries

For inquiries regarding this disclosure policy, please contact us via the inquiry form.

REV

Revision History

  1. v1.1

    Updated to reflect NASDAQ listing (ticker: BIOT), including regulatory filings via SEC/EDGAR and refined disclosure framework.

  2. v1.0

    Initial establishment and publication of the Disclosure Policy.